{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:34:39Z","timestamp":1790116479822,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1053\/j.seminhematol.2020.12.004","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:40:49Z","timestamp":1609155649000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma"],"prefix":"10.1053","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth M","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4250-9422","authenticated-orcid":false,"given":"Reda Z","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahper N","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5605-7020","authenticated-orcid":false,"given":"Jason","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2559-563X","authenticated-orcid":false,"given":"Robert","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babal K","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Campagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Fada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-3261","authenticated-orcid":false,"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-1031","authenticated-orcid":false,"given":"Yogen","family":"Saunthararajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yap","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-8030","authenticated-orcid":false,"given":"Frederic J","family":"Reu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.12.004_bib0002","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0003","unstructured":"Cancer Stat Facts: Myeloma [Internet]. NCI, SEER. 2020 [cited September 22, 2020]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/jcp.2006.036715","article-title":"Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"60","author":"Chim","year":"2007","journal-title":"Journal of clinical pathology"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0005","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0006","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"issue":"9-10","key":"10.1053\/j.seminhematol.2020.12.004_bib0007","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.dnarep.2006.05.012","article-title":"Distinguishing primary and secondary translocations in multiple myeloma","volume":"5","author":"Gabrea","year":"2006","journal-title":"DNA repair"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.12.004_bib0008","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2141.1996.d01-1685.x","article-title":"Molecular alterations of IL-6R, lck and c-myc genes in transforming monoclonal gammopathies of undetermined significance","volume":"93","author":"Gernone","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0009","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V98.1.244","article-title":"p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance","volume":"98","author":"Guillerm","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0010","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","article-title":"Myeloma is characterized by stage-specific alterations in DNA Methylation that occur early during myelomagenesis","volume":"190","author":"Heuck","year":"2013","journal-title":"J Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2141.2003.04577.x","article-title":"Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities","volume":"123","author":"Rasmussen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0012","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","author":"Walker","year":"2013","journal-title":"Leukemia"},{"issue":"25","key":"10.1053\/j.seminhematol.2020.12.004_bib0013","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2020.12.004_bib0014","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.12.004_bib0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2020.12.004_bib0016","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0017","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.12.004_bib0018","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0020","doi-asserted-by":"crossref","first-page":"e66361","DOI":"10.1371\/journal.pone.0066361","article-title":"A novel measure of chromosome instability can account for prognostic difference in multiple myeloma","volume":"8","author":"Chung","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0021","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fonc.2018.00566","article-title":"The epigenome in multiple myeloma: impact on tumor cell plasticity and drug response","volume":"8","author":"De Smedt","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0022","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4161\/nucl.2.5.17928","article-title":"Regulation of DNA methyltransferase 1 by interactions and modifications","volume":"2","author":"Qin","year":"2011","journal-title":"Nucleus"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/genes10020172","article-title":"The roles of human DNA Methyltransferases and their isoforms in shaping the epigenome","volume":"10","author":"Gujar","year":"2019","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/5947","article-title":"Cancer epigenetics comes of age","volume":"21","author":"Jones","year":"1999","journal-title":"Nature genetics"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.12.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0027","first-page":"138","article-title":"DNA hypomethylation and human diseases","volume":"1775","author":"Wilson","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ijc.26320","article-title":"Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo","volume":"131","author":"Alcazar","year":"2012","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0029","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminoncol.2011.11.011","article-title":"p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies","volume":"39","author":"Saunthararajah","year":"2012","journal-title":"Semin Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2020.12.004_bib0030","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1158\/0008-5472.CAN-10-0282","article-title":"DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors","volume":"70","author":"Salhia","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0031","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.12.004_bib0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0033","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12157","article-title":"Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner","volume":"12","author":"Dimopoulos","year":"2018","journal-title":"Mol Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.12.004_bib0034","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2005.03.4074","article-title":"Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation","volume":"24","author":"Reu","year":"2006","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0035","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1158\/0008-5472.CAN-05-2303","article-title":"Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons","volume":"66","author":"Reu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/257695","article-title":"Cancer\/Testis Antigen MAGE-C1\/CT7: new target for multiple myeloma therapy","volume":"2012","author":"de Carvalho","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0037","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.18632\/oncotarget.3207","article-title":"In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma","volume":"6","author":"Maes","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0038","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2141.2012.09225.x","article-title":"Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity","volume":"158","author":"Toor","year":"2012","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.12.004_bib0039","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2005.03.4074","article-title":"Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation","volume":"24","author":"Reu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2020.12.004_bib0040","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-08-3336","article-title":"Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma","volume":"15","author":"Nojima","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.12.004_bib0041","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"The lancet oncology"},{"issue":"17","key":"10.1053\/j.seminhematol.2020.12.004_bib0042","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","article-title":"Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies","volume":"23","author":"Rudek","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.12.004_bib0043","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0044","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/leu.2011.207","article-title":"CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors","volume":"26","author":"Negrotto","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.12.004_bib0045","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.12.004_bib0046","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","article-title":"Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or Decitabine Therapy","volume":"19","author":"Mahfouz","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1053\/j.seminhematol.2020.12.004_bib0047","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0048","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcph.251","article-title":"Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies","volume":"54","author":"Laille","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.12.004_bib0049","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ygeno.2011.07.007","article-title":"High density DNA methylation array with single CpG site resolution","volume":"98","author":"Bibikova","year":"2011","journal-title":"Genomics"},{"issue":"21","key":"10.1053\/j.seminhematol.2020.12.004_bib0050","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0051","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.12.004_bib0052","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4149\/neo_2018_170519N363","article-title":"Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients","volume":"65","author":"Stork","year":"2018","journal-title":"Neoplasma"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.12.004_bib0053","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","article-title":"Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma","volume":"118","author":"Madan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0054","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15504","article-title":"Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients","volume":"183","author":"Oostvogels","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.12.004_bib0055","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2011-08-371690","article-title":"Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine","volume":"119","author":"Lavelle","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.12.004_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0057","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1091581814524994","article-title":"Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice","volume":"33","author":"Terse","year":"2014","journal-title":"Int J Toxicol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.12.004_bib0058","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"The Lancet Haematology"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.12.004_bib0059","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11523-020-00709-x","article-title":"Oral Azacitidine and Cedazuridine approximate parenteral azacitidine efficacy in Murine Model","volume":"15","author":"Ramsey","year":"2020","journal-title":"Target Oncol"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.12.004_bib0061","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.18632\/oncotarget.597","article-title":"High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects","volume":"3","author":"Ebrahem","year":"2012","journal-title":"Oncotarget"},{"issue":"13","key":"10.1053\/j.seminhematol.2020.12.004_bib0062","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"issue":"8","key":"10.1053\/j.seminhematol.2020.12.004_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135520","article-title":"Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies","volume":"10","author":"Laille","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0064","unstructured":"FDA. FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia FDA I Drugs Development & Approval Process | Drugs Drug Approvals and Databases Resources for Information | Approved Drugs FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-onureg-azacitidine-tablets-acute-myeloid-leukemia."},{"key":"10.1053\/j.seminhematol.2020.12.004_bib0065","author":"Wei","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.12.004_bib0066","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1080\/10428194.2019.1571201","article-title":"Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)","volume":"60","author":"Kalff","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0067","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/bjh.16686","article-title":"Addition of low-dose decitabine to bortezomib and dexamethasone as second-line therapy in multiple myeloma","volume":"189","author":"Li","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.12.004_bib0068","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1038\/s41598-019-41070-y","article-title":"Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS\/MS with enzymatic digestion","volume":"9","author":"Chilakala","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.12.004_bib0069","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2018.12.764","article-title":"Low-dose Azacitidine with DNMT1 level monitoring to treat post-transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse","volume":"25","author":"Ueda","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196320300779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196320300779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:26:51Z","timestamp":1758522411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196320300779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0037196320300779"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.12.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}